Mechanism of Proteotoxicity and Experimental Therapeutic Approaches in Porphyria

卟啉症的蛋白质毒性机制和实验治疗方法

基本信息

  • 批准号:
    9469835
  • 负责人:
  • 金额:
    $ 45.01万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-20 至 2020-07-31
  • 项目状态:
    已结题

项目摘要

Abstract Porphyrias are genetic disorders caused by mutations in enzymes involved in eight sequential biosynthetic conversions that combine glycine and succinyl coenzyme-A to generate heme. Porphyrin accumulation can result in `secondary porphyrias' in association with other diseases such as hepatitis C virus infection. Current major unmet needs with regard to the porphyria disorders are our present limited understanding of the molecular triggers of porphyria acute attacks, aside from indirect association with fever or drugs; the reasons why some individuals develop significant end-organ complications such as the need for liver or bone marrow transplantation while others do not; and importantly the limited availability of drugs to treat the different porphyrias. Our central hypothesis is that proteotoxic porphyrin-mediated damage, coupled with modifier effects, contributes to the cellular damage and morbidity that is associated with porphyrias. This hypothesis will be tested by pursuing three specific aims: (i) Define the mechanism of porphyria-induced protein aggregation; (ii) Characterize potential modifiers that promote or protect from porphyria-induced injury in cell culture and animal models; and (iii) Use zebrafish porphyria models to screen and characterize small- molecule compounds that prevent tissue porphyrin accumulation. We have assembled extensive preliminary results to support the likely success of our aims, including substantial evidence for porphyrin-mediated protein aggregation that is dependent on the mode of porphyrin accumulation, evidence for fatty acid binding protein- 1 as a modulator of porphyrin-mediated cell and liver injury, and two novel acute zebrafish porphyria models we generated that are amenable to high-throughput drug screening with potential positive compounds that we propose to validate and characterize. Completion of our proposed aims should provide fundamental knowledge regarding how porphyrins cause protein aggregation, the subcellular compartments that are involved, whether such aggregation is due to direct covalent porphyrin-protein adduct formation, and the mechanism of aggregate turnover. We also anticipate being able to characterize specific porphyrin-binding proteins that regulate the propensity to accumulate porphyrins in cells and tissues. This could provide potential clues as to why some individuals with porphyria develop end-stage liver disease in the absence of concomitant underlying liver disorders, while other patients are spared serious liver-related complications. Importantly, we anticipate that our proposal will allow us to use two powerful novel acute porphyria zebrafish models we have developed to identify potential compounds that may ultimately have therapeutic utility. This proposal uses state-of-the-art technologies, multiple biochemical and animal model tools including zebrafish and mice, and introduces the novel concept of proteotoxicity as an alternative mechanism for porphyria exacerbations and progression.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bishr Omary其他文献

Bishr Omary的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bishr Omary', 18)}}的其他基金

Mechanism of Proteotoxicity and Experimental Therapeutic Approaches in Porphyria
卟啉症的蛋白质毒性机制和实验治疗方法
  • 批准号:
    10445775
  • 财政年份:
    2017
  • 资助金额:
    $ 45.01万
  • 项目类别:
Mechanism of Proteotoxicity and Experimental Therapeutic Approaches in Porphyria
卟啉症的蛋白质毒性机制和实验治疗方法
  • 批准号:
    9753724
  • 财政年份:
    2017
  • 资助金额:
    $ 45.01万
  • 项目类别:
Mechanism of Proteotoxicity and Experimental Therapeutic Approaches in Porphyria
卟啉症的蛋白质毒性机制和实验治疗方法
  • 批准号:
    10588162
  • 财政年份:
    2017
  • 资助金额:
    $ 45.01万
  • 项目类别:
Michigan IRACDA: Training Future Professors of Engineering and Physiology
密歇根 IRACDA:培训未来的工程和生理学教授
  • 批准号:
    9900910
  • 财政年份:
    2016
  • 资助金额:
    $ 45.01万
  • 项目类别:
Michigan IRACDA: Training Future Professors of Engineering and Physiology
密歇根 IRACDA:培训未来的工程和生理学教授
  • 批准号:
    9324272
  • 财政年份:
    2016
  • 资助金额:
    $ 45.01万
  • 项目类别:
Genetic influences in experimental pancreatitis
实验性胰腺炎的遗传影响
  • 批准号:
    8597923
  • 财政年份:
    2012
  • 资助金额:
    $ 45.01万
  • 项目类别:
Genetic influences in experimental pancreatitis
实验性胰腺炎的遗传影响
  • 批准号:
    8965966
  • 财政年份:
    2012
  • 资助金额:
    $ 45.01万
  • 项目类别:
Genetic influences in experimental pancreatitis
实验性胰腺炎的遗传影响
  • 批准号:
    8244910
  • 财政年份:
    2012
  • 资助金额:
    $ 45.01万
  • 项目类别:
Genetic influences in experimental pancreatitis
实验性胰腺炎的遗传影响
  • 批准号:
    8762421
  • 财政年份:
    2012
  • 资助金额:
    $ 45.01万
  • 项目类别:
Pathogenesis of Keratin-Containing Inclusions in Liver Disease
肝脏疾病中含角蛋白包涵体的发病机制
  • 批准号:
    7905576
  • 财政年份:
    2009
  • 资助金额:
    $ 45.01万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.01万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 45.01万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.01万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.01万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.01万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.01万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.01万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 45.01万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 45.01万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 45.01万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了